Targeting full commercilaisation of its patented and world-leading drugs-of-abuse testing technology.<\/b><\/p>\n
OnMarket Live Offer for Professional & Sophisticated Investors: <\/b><\/p>\n
https:\/\/www.onmarket.com.au\/offers\/neopharma-w<\/a><\/b><\/p>\n www.neopharmatechnologies.com\/investor<\/a><\/b> <\/b><\/p>\n PERTH, Australia<\/span>, Oct. 6, 2021<\/span> \/PRNewswire\/ — Neopharma Technologies Ltd is the owner and operator of a globally patented, trademarked and award winning Drugs-of-Abuse testing device and Enterprise Resource Management platform: TamperLoks DataVault. <\/p>\n "Today we are excited to announce that with we have partnered with OnMarket: Australia’s<\/span> largest investment and capital raising platform,<\/span>" said Shaun Melville Global Head of Sales & Marketing for Neopharma Technologies. <\/i><\/p>\n Neopharma Technologies is in the commercialisation stage for its market leading technology and has a number of global distribution agreements in place including in Australasia, Indonesia<\/span>, Malaysia<\/span> and Phillipines. The company has also recently been recognised as a Top 100 Healthcare Technology company for 2021<\/b> by New York<\/span> based company Healthcare Technology Report. <\/p>\n "We felt the timing was right in launching our Pre-IPO investment round. With our award winning technologies at commercisation stage we are well positioned to be a be a global leader in the growing US$6bn<\/span> drugs-of-abuse testing market,<\/span><\/i>" said Shaun Melville<\/span>.<\/i><\/p>\n The TamperLoks DataVault technology takes the physical needs of mandatory drug testing and introduced advanced data collection and management to deliver certainty with complete chain-of-custody and the significant increases in productivity and accuracy that comes with digitising a previously manual process.<\/p>\n There is no current comparable hardware and technology pairing in the market globally that can match the TamperLoks DataVault offering. <\/i><\/p>\n Neopharma Technologies is raising up to $850,000<\/span> at a pre-money equity valuation of $6.7<\/span> AUD million and is targeting an ASX IPO in the next 12-18 months.<\/i><\/p>\n "We are pleased to have partnered with Neopharma Technologies as Lead Manager to this wholesale offer, and are excited about the prospects for the business as it moves toward commercialistion,<\/span>" said Managing Director of OnMarket Nick Motteram<\/span><\/i><\/p>\n About OnMarket <\/b><\/p>\n OnMarket is Australia’s<\/span> largest equity raising platform. OnMarket has raised more funds, for more small to medium sized businesses, from more investors, than any other platform in Australia<\/span>.<\/p>\n Combined, the OnMarket team has over 140 years’ experience in the Australian capital raising market. We know that raising capital can be a difficult process, particularly for early stage and\/or smaller companies. We work to make raising equity efficient, simple and transparent for both companies and investors.<\/p>\n About Neopharma Technologies Ltd<\/b><\/p>\n Neopharma Technologies Ltd is a public unlisted Australian Company. Its strategic vision is to be the global leader in drugs-of-abuse early intervention, through reliable testing, management and rehabilitation. It is the owner and operator of a globally patented, trademarked and award winning Drugs-of-Abuse testing device and Enterprise Resource Management platform: TamperLoks DataVault (TLDV). <\/p>\n For more information visit: www.neopharmatechnologies.com<\/a> <\/p>\n Contact<\/b><\/p>\n Shaun Melville<\/span> Related Links :<\/p>\n
Global Sales & Marketing
Neopharma Technologies Ltd
Level 4, 16 St Georges Tce Perth Western Australia 6000
(e) shaun@neopharmatechnologies.com<\/a><\/p>\n